Investing in innovation: The relationship between R&D spending and financial performance in the European pharmaceutical industry
Keywords:
R&D investment, financial performance, pharmaceutical industry, and Europe.Abstract
The pharmaceutical sector is a highly capital and knowledge-intensive industry in the world, which spends around 15 % of its total revenue on research and development activities. The study aims to find the relationship between pharmaceutical businesses' financial performance and investments made in drug research and development in Europe. The study employs regression analysis with a time-lag effect of R&D spending on the operating earnings model. It is expected in the hypothesis that the investment expenditure of the previous year’s R&D investment will significantly and concurrently impact the economic-financial performance of the country and the findings show a strong and positive link between the previous year’s R&D expenditure and the current year's operating profit in the European countries, providing convincing evidence that R&D investments will pay off financially in the years ahead for the development of pharmaceuticals. The study also conducted diagnosis tests for the validation of the estimated models.
References
Atkinson, A. C., Riani, M., & Torti, F. (2016). Robust methods for heteroskedastic regression. Computational Statistics & Data Analysis, 104, 209-222. https://doi.org/10.1016/j.csda.2016.07.002
Ayaydın, H. & Karaaslan, I. (2014). The Effect Of Research And Development Investment On Firms’ Financial Performance: Evidence From Manufacturing Firms In Turkey . Bilgi Ekonomisi ve Yönetimi Dergisi , 9 (1) , 23-39 . Retrieved from https://dergipark.org.tr/en/pub/beyder/issue/3470/47199
Azierta (2019), Pharmaceutical market in EU, Roma – 08940 Barcelona, available at: www.azierta.com/en/blog/azierta/pharmaceutical-market-in-EU
Bai, J., & Ng, S. (2005). Tests for skewness, kurtosis, and normality for time series data. Journal of Business & Economic Statistics, 23(1), 49-60. https://doi.org/10.1198/073500104000000271
Banerjee, T. and Siebert, R. (2017), Dynamic impact of uncertainty on R&D cooperation formation and research performance: evidence from the biopharmaceutical industry, Research Policy, Vol. 46 No. 7, pp. 1255-1271. https://doi.org/10.1016/j.respol.2017.05.009
Baranov, A., & Muzyko, E. (2015). Valuation of compound real options for investments in innovative projects in pharmaceutical industry. Procedia Economics and Finance, 27, 116-125. https://doi.org/10.1016/S2212-5671(15)00980-6
Bockova, N., & Zizlavsky, O. (2016). Innovation And Financial Performance Of A Company: A Study From Czech Manufacturing Industry. Transformations in business & economics, 15(3).
Boldeanu, D. M., & Pugna, I. B. (2014). The analysis of the influence factors affecting the performance of pharmaceutical companies. Theoretical & Applied Economics, 21(7).
Breusch, T. S., & Pagan, A. R. (1979). A simple test for heteroscedasticity and random coefficient variation. Econometrica: Journal of the econometric society, 1287-1294. https://doi.org/10.2307/1911963
Campbell, M. (2012). What a difference a year makes: time lag effect of information technology investment on firm performance. Journal of Organizational Computing and Electronic Commerce, 22(3), 237-255. https://doi.org/10.1080/10919392.2012.696944
Chan, H.S., Shan, H., Dahoun, T., Vogel, H. and Yuan, S. (2019), Advancing drug discovery via artificial intelligence, Trends in Pharmacological Sciences, Vol. 40 No. 8, pp. 592-604. https://doi.org/10.1016/j.tips.2019.06.004
Chaudhuri, A. (2013), Simultaneous improvement in development time, cost and quality: a practical framework for generic pharmaceuticals industry, R&D Management, Vol. 43 No. 3, pp. 227-241. https://doi.org/10.1111/j.1467-9310.2012.00675.x
Chen, M., Cheng, S. and Hwang, Y. (2005). An empirical investigation of the relationship between intellectual capital and firms’ market value and financial performance, Journal of Intellectual Capital, 6 (2), 159-176. https://doi.org/10.1108/14691930510592771
Chit, A., & Grootendorst, P. (2018). Policy to encourage the development of antimicrobials. International Journal of Health Governance, 23 (2), pp. 101-110. https://doi.org/10.1108/IJHG-12-2017-0062
Cockburn, I., & Long, G. (2015). The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals. Expert opinion on therapeutic patents, 25(7), 739-742. https://doi.org/10.1517/13543776.2015.1040762
Cowlrick, I., Hedner, T., Wolf, R., Olausson, M. and Klofsten, M. (2011), Decision-making in the pharmaceutical industry: analysis of entrepreneurial risk and attitude using uncertain information, R&D Management, Vol. 41 No. 4, pp. 321-33. https://doi.org/10.1111/j.1467-9310.2011.00649.x
Deng, P., Lu, H., Hong, J., Chen, Q., & Yang, Y. (2019). Government R&D subsidies, intellectual property rights protection and innovation. Chinese Management Studies, 13(2), 363-378. https://doi.org/10.1108/CMS-02-2018-0422
Desmet, K., Kujal, P., and Lobo, F. (2004). Implementing R&D policies: An analysis of Spain’s pharmaceutical research program. Research Policy, Vol.33, No.10, pp.1493–1507. https://doi.org/10.1016/j.respol.2004.07.007
Downs, J.B. and Velamuri, V.K. (2018), Business model innovation in a knowledge revolution: an evolutionary theory perspective, Managerial and Decision Economics, Vol. 39 No. 5, pp. 550-562. https://doi.org/10.1002/mde.2926
Dubey, J. and Dubey, R. (2010), "Pharmaceutical innovation and generic challenge: recent trends and causal factors", International Journal of Pharmaceutical and Healthcare Marketing, Vol. 4 No. 2, pp. 175-190. https://doi.org/10.1108/17506121011059777
E., Lisdawati, D. S., Hakim, L., & Sugianto, S. (2020). Determinants of profitability: Evidence of the pharmaceutical industry in Indonesia. Systematic Reviews in Pharmacy Endri,, 11(6), 587-597. DOI: 10.31838/srp.2020.6.89
European Commission (2021), “A pharmaceutical strategy for Europe: challenges facing the sector”, available at: https://ec.europa.eu/health/human-use/strategy_en.
European Commission (2022). EU Industrial R&D Investment Scoreboard, available at: https://iri.jrc.ec.europa.eu/data
Faems, D., De Visser, M., Andries, P., & Van Looy, B. (2010). Technology alliance portfolios and financial performance: value‐enhancing and cost‐increasing effects of open innovation. Journal of Product Innovation Management, 27(6), 785-796. doi:10.1111/j.1540-5885.2010.00752.x
Freihat, A. R. F., & Kanakriyah, R. (2017). Impact of R&D expenditure on financial performance: Jordanian evidence. European Journal of Business and Management, 9(32), 73-83.
Frigyesi, V., Laget, P., & Boden, M. (2019). Exploitation of patent information in R&D output analysis for policymaking. Scientometrics, 121(3), 1717-1736. https://doi.org/10.1007/s11192-019-03236-3
Gassmann, O., Reepmeyer, G., & von Zedtwitz, M. (2008). Innovation: key to success in the pharmaceutical industry. Leading Pharmaceutical Innovation: Trends and Drivers for Growth in the Pharmaceutical Industry, 1-18. https://doi.org/10.1007/978-3-540-77636-9_1
Geer, M. I. (2023). Stakeholders in Pharmaceutical Policy Development. IntechOpen. doi: 10.5772/intechopen.105606
Goldman, M. (2012), The innovative medicines initiative: a European response to the innovation challenge, Clinical Pharmacology & Therapeutics, Vol. 91 No. 3, pp. 418-425. https://doi.org/10.1038/clpt.2011.321
Grassano, N., Hernandez Guevara, H., Fako, P., Nindl, E., Georgakaki, A., Ince, E., Napolitano, L., Rentocchini, F. and Tübke, A. (2022) The EU Industrial R&D Investment Scoreboard (2022). European Commission. Retreived from: https://iri.jrc.ec.europa.eu/scoreboard/2022-eu-industrial-rd-investment-scoreboard
Greer, S.L., Rozenblum, S., Fahy, N., Brooks, E., Jarman, H., de Ruijter, A. and Wismar, M. (2014), Everything you always wanted to know about European union health policies but were afraid to ask, European Observatory on Health System and Policies, UK. ISBN 978 92 890 59 022
Hanekom, N., Bam, L. and Kock, I. d (2019), What makes diseases and drug research and development attractive for the pharmaceutical industry, 2019 IEEE International Conference on Engineering, Technology and Innovation (ICE/ITMC), pp. 1-9. doi: 10.1109/ICE.2019.8792645.
Horrobin, D. F. (2000). Innovation in the pharmaceutical industry. Journal of the Royal Society of Medicine, 93(7), 341-345.
Houÿez, F. (2020). High Price Medicines and Health Budgets: The Role Patients’ and Consumers’ Organisations Can Play, European Journal of Health Law, 27(3), 309-323. doi: https://doi.org/10.1163/15718093-BJA10008
Jaisinghani, D. (2016), Impact of R&D on profitability in the pharma sector: an empirical study from India, Journal of Asia Business Studies, Vol. 10 No. 2, pp. 194-210. https://doi.org/10.1108/JABS-03-2015-0031
Kale, D., & Little, S. (2007). From imitation to innovation: The evolution of R&D capabilities and learning processes in the Indian pharmaceutical industry. Technology Analysis & Strategic Management, 19(5), 589-609. https://doi.org/10.1080/09537320701521317
Kor, Y.Y. and Mahoney, J.T. (2005). How dynamics, management, and governance of resource deployments influence firm-level performance. Strat. Mgmt. J., 26: 489-496 https://doi.org/10.1002/smj.459
Kounnou, V., Kyrkilis, D. (2020). Competitiveness, Profitability and R/D Intensity: The Case of the Domestic Pharmaceutical Industry in Greece. In: Horobet, A., Polychronidou, P., Karasavvoglou, A. (eds) Business Performance and Financial Institutions in Europe. Contributions to Economics. Springer, Cham. https://doi.org/10.1007/978-3-030-57517-5_3
le Deu, F. and Santos Da Silva, J. (2019), Pharmaceuticals and medical products biotech in Europe: a strong foundation for growth and innovation. Available at: https://www.coursehero.com/file/78032517/mckinsey-Biotech-in-Europepdf/
Islam, M. S., & Khan, M. S. (2019). The determinants of profitability of the pharmaceutical industry of Bangladesh: A random effect analysis. International Journal of Financial Research, 10(2), 68-74. doi:10.5430/ijfr.v10n2p68
Lee, S., & Kim, S. H. (2006). A lag effect of IT investment on firm performance. Information Resources Management Journal (IRMJ), 19(1), 43-69. DOI: 10.4018/irmj.2006010103
Lee, M., & Choi, M. (2015). The determinants of research and development investment in the pharmaceutical industry: focus on financial structures. Osong public health and research perspectives, 6(5), 302-309. https://doi.org/10.1016/j.phrp.2015.10.013
Leten, B., Belderbos, R. and Van Looy, B. (2011), Technological diversification, coherence and performance of firms, SSRN Electronic Journal, pp. 567-579. https://doi.org/10.1111/j.1540-5885.2007.00272.x
Leten, B., Kelchtermans, S., & Belderbos, R. (2022). How does basic research improve innovation performance in the world’s major pharmaceutical firms?. Industry and Innovation, 29(3), 396-424. https://doi.org/10.1080/13662716.2021.1997723
Lim, H. and Rokhim, R. (2021). Factors affecting profitability of pharmaceutical company: an Indonesian evidence, Journal of Economic Studies, Vol. 48 No. 5, pp. 981-995. https://doi.org/10.1108/JES-01-2020-0021
Logviss, K., Krievins, D. and Purvina, S. (2014), Trends in individual reimbursement of orphan drugs in Latvia in 2008–2011, SHS Web of Conferences, Vol. 10, p. 21. https://doi.org/10.1051/shsconf/20141000021
Magazzini, L., Pammolli, F. and Riccaboni, M. (2016), Real options and incremental search in pharmaceutical R&D project portfolio management, Creativity and Innovation Management, Vol. 25 No. 2, pp. 292-302. https://doi.org/10.1111/caim.12119
Maja Pervan, M. & Kramaric, T.P. (2020). Impact Of Research and Development Expenditure on Firm Performance. The 14th International Days of Statistics and Economics, Prague, September 10-12, 2020
Mazzola, E., Bruccoleri, M., & Perrone, G. (2016). Open innovation and firms performance: State of the art and empirical evidences from the bio-pharmaceutical industry. International Journal of Technology Management, 70(2-3), 109-134.
Mennini, F.S., Gitto, L., Scrivo, R., Drago, F., Iezzi, M., Terranova, L. and Cicchetti, A. (2016), The promotion of drug innovation in Italy: critical aspects and unsolved problems, Global & Regional Health Technology Assessment, Vol. 3 No. 1, pp. 42-47. https://doi.org/10.5301/GRHTA.5000216
Mesko, B (2021). Future of Pharma. The Medical Futurist. Retrieved from: https://medicalfuturist.com/category/future-of-pharma/
Morgan, S., Lopert, R., & Greyson, D. (2008). Toward a definition of pharmaceutical innovation. Open medicine, 2(1), e4. Epub 2008 Jan 30. PMID: 21602949; PMCID: PMC3091590.
Murphy, K. J., & Zimmerman, J. L. (1993). Financial performance surrounding CEO turnover. Journal of Accounting and Economics, 16(1-3), 273-315. doi:10.1016/0165-4101(93)90014-7.
Nandy, M. (2020). Is there any impact of R&D on financial performance? Evidence from Indian pharmaceutical companies. FIIB Business Review, 9(4), 319-334. DOI: 10.1177/2319714520981816.
OECD, E.U. (2020), “Health at a glance: Europe 2020: state of in the EU cycle”, Health at a Glance 2007.
Paranhos, J., & Hasenclever, L. (2011). Is industry–university interaction promoting innovation in the Brazilian pharmaceutical industry?. Industry and Higher Education, 25(5), 397-407. DOI:10.5367/ihe.2011.0060
Parsons, S., Starling, B., Mullan-Jensen, C., Tham, S.G., Warner, K. and Wever, K. (2016), What do pharmaceutical industry professionals in Europe believe about involving patients and the public in research and development of medicines? A qualitative interview study, BMJ Open, Vol. 6 No. 1, pp. 1-12. http://dx.doi.org/10.1136/bmjopen-2015-008928
Pazarzi, G., & Sorros, J. (2018). The effect of R&D expenses on earnings and market value. SPOUDAI-Journal of Economics and Business, 68(2/3), 39-47. http://hdl.handle.net/10419/195213
Rake, B. (2017). Determinants of pharmaceutical innovation: the role of technological opportunities revisited. Journal of Evolutionary Economics, 27(4), 691-727. https://doi.org/10.1007/s00191-017-0524-6
Rollet, P., Lemoine, A., & Dunoyer, M. (2013). Sustainable rare diseases business and drug access: no time for misconceptions. Orphanet journal of rare diseases, 8(1), 1-9. https://doi.org/10.1186/1750-1172-8-109
Schilling, E. G., & Nelson, P. R. (1976). The effect of non-normality on the control limits of X charts. Journal of Quality Technology, 8(4), 183-188. https://doi.org/10.1080/00224065.1976.11980743
Sieg, J. H., Wallin, M. W., & Von Krogh, G. (2010). Managerial challenges in open innovation: a study of innovation intermediation in the chemical industry. R&d Management, 40(3), 281-291. https://doi.org/10.1111/j.1467-9310.2010.00596.x
Tang, Z., Hull, C.E. and Rothenberg, S. (2012), How Corporate Social Responsibility Engagement Strategy Moderates the CSR–Financial Performance Relationship. Journal of Management Studies, 49: 1274-1303. https://doi.org/10.1111/j.1467-6486.2012.01068.x
Theuretzbacher, U. (2012), Accelerating resistance, inadequate antibacterial drug pipelines, and international responses, International Journal of Antimicrobial Agents, Vol. 39 No. 4, pp. 295-299. https://doi.org/10.1016/j.ijantimicag.2011.12.006
Timmerman, P., Henderson, N., Smeraglia, J., Mulder, H., Ingelse, B., Brudny-Kloeppel, M. and Companjen, A. (2013), Managing scientific, technical and regulatory innovation in regulated bioanalysis: a discussion paper from the European bioanalysis forum, Bioanalysis, Vol. 5 No. 2, pp. 139-145. https://doi.org/10.4155/bio.12.267
Towse, A. and Sharma, P. (2011), Incentives for R&D for new antimicrobial drugs, International Journal of the Economics of Business, Vol. 18 No. 2, pp. 331-350. https://doi.org/10.1080/13571516.2011.584434
Tyagi, S. & Nauriyal, D.K. (2017). Firm level profitability determinants in Indian drugs and pharmaceutical industry. International Journal of Pharmaceutical and Healthcare Marketing, Vol. 11 No. 3, pp. 271-290. https://doi.org/10.1108/IJPHM-03-2016-0016
Tyagi, S., Nauriyal, D. K., & Gulati, R. (2018). Firm level R&D intensity: evidence from Indian drugs and pharmaceutical industry. Review of Managerial Science, 12, 167-202. https://doi.org/10.1007/s11846-016-0218-8
VanderPal, G. A. (2015). Impact of R&D expenses and corporate financial performance. Journal of Accounting and Finance, 15(7), 135-149.
Xie, H., Yang, J., Yu, W., Yang, Y., & Wu, W. (2020). The Time-lag Effect of R&D Investment on the Value of Listed Companies in China: A Cross-industry Analysis. Journal of Creating Value, 6(2), 217-231. https://doi.org/10.1177/2394964320923543
Yousefi, N., Mehralian, G., Rasekh, H. R., & Yousefi, M. (2017). New Product Development in the Pharmaceutical Industry: Evidence from a generic market. Iranian journal of pharmaceutical research: IJPR, 16(2), 834. PMID: 28979339; PMCID: PMC5603895.
Zambuto, F., Lo Nigro, G., & O'Brien, J. P. (2017). The importance of alliances in firm capital structure decisions: evidence from biotechnology firms. Managerial and Decision Economics, 38(1), 3-18. https://doi.org/10.1002/mde.2735
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Arif Ibne Asad, Lubor Homolka
This work is licensed under a Creative Commons Attribution 4.0 International License.
The JEECAR journal allows the author(s) to hold the copyright and publishing rights of their own manuscript without restrictions.
This journal applies the Creative Attribution Common License to works we publish, and allows reuse and remixing of its content, in accordance with a CC-BY 4.0 license.
Authors are free to: Share — copy and redistribute the material in any medium or format and Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — The author may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
The JEECAR Journal is committed to the editorial principles of all aspects of publication ethics and publication malpractice as assigned by the Committee on Public Ethics.
